Vertex Pharmaceuticals Incorporated Financials

Market Capitalization $113.24 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	32.82
Forward PE	23.43
Price to Sales TTM	$10.66
Price to Book MRQ	$7.25
Enterprise to Revenue	10.21
Enterprise to EBITDA	24.40

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-4.51%
Operating Margin	40.82%
Return on Assets TTM	12.05%
Return on Equity TTM	-2.98%

Income Statement

Revenue TTM	$10,625,800,192
Revenue per Share TTM	$41.19
Quarterly Revenue Growth	11.60%
Gross Profit TTM	$5,694,499,840
EBITDA	$5,026,800,000
Net Income to Common TTM	$-479,800,000
Diluted EPS TTM	$-1.89
Quarterly Earnings Growth YoY	1.00%

Balance Sheet

Total Cash MRQ	$6,524,499,968
Total Cash per Share MRQ	$25.34
Total Debt MRQ	$
Total Debt to Equity MRQ	11.35
Current Ratio MRQ	2.47
Book Value per Share MRQ	$60.65

Cash Flow

Operating Cash Flow TTM	$-842,600,000
Levered Free Cash Flow TTM	$3,063,387,392

VRTX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	257,528,992
Float Shares	256,754,127
Avg 10 Volume	1,525,410
Avg 30 Volume	None
Shares Short	3,955,628
Short Ratio	2.15
Short % of Shares	1.54%
% Held by Insiders	0.08%
% Held by Institutions	96.01%

Stock Price Summary

Beta	0.39
Fifty Two Week Low	$377.85
Fifty Two Week High	$519.88
Fifty Two Week Change	0.86%
Day 50 MA	$443.45
Day 200 MA	$457.67

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2000-08-24